A61K 9 - Medicinal preparations characterised by special physical form

Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
08/2011
08/30/2011	CA2479665C Nanoparticulate compositions of angiogenesis inhibitors
08/30/2011	CA2414950C Method and kit for moisturizing the surface of the eye
08/25/2011	WO2011103436A1 Rapid-release encapsulation composition
08/25/2011	WO2011103413A2 Taxane pro-emulsion formulations and methods making and using the same
08/25/2011	WO2011103382A2 Compositions and methods for inducing angiogenesis
08/25/2011	WO2011102787A1 Process for preparation of crystalline nano-particle suspensions
08/25/2011	WO2011102724A2 Disinfectant composition and its use in dental treatment
08/25/2011	WO2011102702A2 Process for the preparation of oral solid dosage forms comprising valsartan
08/25/2011	WO2011102657A2 Composition for percutaneous administration of tolterodine with improved skin permeation
08/25/2011	WO2011102506A1 Sustained-release solid preparation for oral use
08/25/2011	WO2011102505A1 Sustained-release solid preparation for oral use
08/25/2011	WO2011102504A1 Sustained-release solid preparation for oral use
08/25/2011	WO2011102407A1 Radiation therapy agent
08/25/2011	WO2011101868A2 Stable pharmaceutical preparations containing clindamycin and benzoyl peroxide and method thereof
08/25/2011	WO2011101866A2 A method of treating a disease condition susceptible to baclofen therapy
08/25/2011	WO2011101863A2 Extended release pharmaceutical compositions of lacosamide
08/25/2011	WO2011101862A1 Stabilized fluconazole polymorph iii formulation
08/25/2011	WO2011101860A1 Nicotine-containing soft gelatin pastilles
08/25/2011	WO2011101859A1 A novel water soluble curcumin loaded nanoparticulate system for cancer therapy
08/25/2011	WO2011101830A1 A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer and clobetasone, and a process to make it
08/25/2011	WO2011101828A1 A medicinal fusidic acid cream made using sidium fusidate and incorporating a biopolymer and betamethasone, and a process to make it
08/25/2011	WO2011101826A1 A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, terbinafine and dexamethasone, and a process to make it
08/25/2011	WO2011101825A1 A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, clotrimazole and clobetasone, and a process to make it
08/25/2011	WO2011101824A1 A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, miconazole, dexamethasone, and a process to make it
08/25/2011	WO2011101823A1 A medicinal fusidic acid cream made using sodium fusidate and incorporating biopolymer, clotrimazole and dexamethasone, and a process to make it
08/25/2011	WO2011101802A1 Citicoline for the treatment of glaucoma and ocular hypertension
08/25/2011	WO2011101734A2 Taste-masked powder for suspension compositions of methylprednisolone
08/25/2011	WO2011101602A1 Nanoemulsion for the delivery of at least two agents of interest
08/25/2011	WO2011101465A1 Ic31 nanoparticles
08/25/2011	WO2011101456A2 Stabilized phenylcarbamate derivative in solid state
08/25/2011	WO2011101420A1 Preparation of functionalized nano/micro-structures by self-assembly of biomolecules
08/25/2011	WO2011101415A1 Liquid-filled chitosan-anionic liposoluble surfactant capsule dispersions
08/25/2011	WO2011101352A2 Test solvent for evaluating the compatibility of biologically active substances and graft copolymers
08/25/2011	WO2011101340A1 Zeolite-containing preparations containing clinoptilolite and uses thereof
08/25/2011	WO2011101171A1 Nutritional composition
08/25/2011	WO2011100975A2 Stabilized tacrolimus composition
08/25/2011	WO2011078457A3 Ph-sensitive block copolymer forming polyionic complex micelle, and drug or protein delivery vehicle using same
08/25/2011	WO2011048553A3 Pharmaceutical compositions of pde-5 inhibitors and dapoxetine
08/25/2011	WO2011037976A3 Pramipexole pharmaceutical formulations
08/25/2011	WO2011012637A3 Subcutaneous anti-her2 antibody formulation
08/25/2011	WO2011009797A3 Plasma-adapted and balanced gelatin solution
08/25/2011	WO2011003822A3 Aqueous insulin preparations containing methionine
08/25/2011	WO2010142660A3 Microparticles comprising sirna
08/25/2011	US20110208168 Particle formulations for use in pharmaceutical compositions
08/25/2011	US20110207787 Antimicrobial compositions
08/25/2011	US20110207740 Pharmaceutical compositions
08/25/2011	US20110206800 Non-digestible sugar-coated products and process
08/25/2011	US20110206773 Sustained delivery of drugs from biodegradable polymeric microparticles
08/25/2011	US20110206772 Polysaccharide composition and methods of isolation of the emulsion stabilizing cationic polyelectrolytic polysaccharide
08/25/2011	US20110206771 Encapsulated functional fine particle composition capable of spraying and preparation method thereof
08/25/2011	US20110206770 Atovaquone with a particle size diameter range (d90) of greater than 3 microns to about 10 microns
08/25/2011	US20110206769 Oral antidepressant formulation with reduced excipient load
08/25/2011	US20110206768 Medical preparation
08/25/2011	US20110206767 Pharmaceutical composition
08/25/2011	US20110206766 Dpp-iv inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
08/25/2011	US20110206765 Non-Typeable Haemophilus Influenzae Vaccines and Their Uses
08/25/2011	US20110206764 Formulations for enhanced bioavailability of orally administered polar agents
08/25/2011	US20110206763 Rapid-release encapsulation composition
08/25/2011	US20110206762 Oral pharmaceutical formulation of pelubiprofen with improved dissolution rate and stability
08/25/2011	US20110206761 Stable dosage forms of antihypertensive agents
08/25/2011	US20110206760 Angiopoietin derived peptides
08/25/2011	US20110206759 Ccr7 ligand delivery and co-delivery in immunotherapy
08/25/2011	US20110206758 Vaccine Compositions Comprising a Saponin Adjuvant
08/25/2011	US20110206757 Novel glycoconjugates, glycoamino acids, intermediates thereto, and uses thereof
08/25/2011	US20110206756 Dithiocarbamate metal chelates and methods of making and using thereof
08/25/2011	US20110206755 Methods and products for manipulating uncoupling protein expression
08/25/2011	US20110206752 Compositions for the treatment of pain and/or inflamation
08/25/2011	US20110206751 Stimulatable asymmetrical polymersome
08/25/2011	US20110206747 Multiplication of the efficacy of anti-infectious agents by a composition further comprising a dispersing agent together with a metal activating agent
08/25/2011	US20110206745 Octreotide implant having a release agent
08/25/2011	US20110206744 Modafinil formulations
08/25/2011	US20110206743 Nutritional compositions with lipid globules with a core comprising vegetable lipids and a coating comprising phospholipids or polar lipids
08/25/2011	US20110206742 Immunotherapeutic compositions for the treatment of alzheimer's disease
08/25/2011	US20110206741 DHA Triglyceride Emulsions
08/25/2011	US20110206740 Cell Membrane Engineering
08/25/2011	US20110206739 Compositions and methods for the preparation of nanoemulsions
08/25/2011	US20110206738 Feline stimulant and method of manufacture
08/25/2011	US20110206737 Photosensitizer-containing composition
08/25/2011	US20110206631 Ion binding polymers and uses thereof
08/25/2011	US20110206622 Effervescent Compositions Comprising Phosphonates and Methods Related Thereto
08/25/2011	US20110206621 Oral transmucosal nicotine dosage form
08/25/2011	US20110206620 Therapeutic Compositions for the Treatment of Dry Eye Disease
08/25/2011	US20110206619 Gold coated super paramagnetic iron oxide nano-particles (spions) and a method of synthesizing the same
08/25/2011	US20110206610 Compositions and methods for enhancing drug delivery across and into epithelial tissues
08/25/2011	US20110204533 Emulsion-Based Process for Preparing Microparticles and Workhead Assembly for Use with Same
08/25/2011	US20110204085 Fluid-jet medicament delivery
08/25/2011	CA2790790A1 Nutritional composition
08/25/2011	CA2790164A1 Method of treating a disease condition susceptible to baclofen therapy
08/25/2011	CA2789257A1 Rapid-release encapsulation composition
08/24/2011	EP2360253A1 RNA sequence-specific mediators of RNA interference
08/24/2011	EP2360252A1 Immunostimulatory nucleic acid molecules comprising GTCGTT motifs
08/24/2011	EP2360173A1 Cytotoxic t cell epitope peptide for sars coronavirus, and use thereof
08/24/2011	EP2360159A1 Prasugrel in micronized, crystalline form and pharmaceutical compound of same
08/24/2011	EP2359861A1 Inclusion complexes of pinocembrin with cyclodextrin or its derivatives
08/24/2011	EP2359859A1 Compositions comprising albumin nanoparticles and methods of delivery of pharmacological agents
08/24/2011	EP2359856A1 Formulation of human antibodies for treating TNF-alpha associated disorders
08/24/2011	EP2359852A1 Novel cancer targeting therapy using complex of substance capable of binding specifically to constituent factor of cancer stroma and anti-tumor compound
08/24/2011	EP2359850A1 Single-time vaccines
08/24/2011	EP2359845A1 Inhalant comprising modified superoxide dismutase
08/24/2011	EP2359830A1 Controlled released preparations of oxcarbazepine having sigmoidal release profile

1 ... 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 ... 2991